Bone disease is a recognised complication of the early post-transplant period. This protocol specifically addresses renal osteodystrophy in patients who have undergone kidney transplantation and present with low bone mineral density within the first year.
This scenario applies to patients in the first 12 months after kidney transplantation with an estimated glomerular filtration rate (eGFR) greater than approximately 30 ml/min/1.73 m² and evidence of low bone mineral density (BMD). The combination of recent transplant history, preserved but reduced kidney function, and low BMD defines this distinct clinical subgroup.
In this setting, treatment may involve vitamin D-based therapy as part of a broader bone-protective strategy. The complete regimen — including specific agents, combinations, and clinical decision points — is available in the full structured protocol.
DOI: 10.1038/ki.2009.191
In patients in the first 12 months after kidney transplant with an estimated glomerular filtration rate greater than approximately 30 ml/min/1.73 m² and low BMD, we suggest that treatment with vitamin D, calcitriol/alfacalcidol, and/or antiresorptive agents be considered (2D).
View source ↗